Anne L Angiolillo1,2, Reuven J Schore1,2, John A Kairalla3, Meenakshi Devidas4, Karen R Rabin5, Patrick Zweidler-McKay6, Michael J Borowitz7, Brent Wood8, Andrew J Carroll9, Nyla A Heerema10, Mary V Relling11, Johann Hitzler12, Ashley R Lane1, Kelly W Maloney13, Cindy Wang3, Mylène Bassal14, William L Carroll15, Naomi J Winick16, Elizabeth A Raetz15, Mignon L Loh17, Stephen P Hunger18. 1. Children's National Medical Center, Washington, DC. 2. George Washington University School of Medicine and Health Sciences, Washington, DC. 3. Department of Biostatistics, Colleges of Medicine and Public Health & Health Professions, University of Florida, Gainesville, FL. 4. Department of Global Pediatric Medicine, St Jude Children's Research Hospital, Memphis, TN. 5. Texas Children's Cancer Center, Baylor College of Medicine, Houston, TX. 6. ImmunoGen, Inc., Boston, MA. 7. Department of Pathology, Johns Hopkins Medical Institutions, Baltimore, MD. 8. Department of Laboratory Medicine, University of Washington, Seattle, WA. 9. Department of Genetics, University of Alabama at Birmingham, AL. 10. Department of Pathology, The Ohio State University Wexner Medical Center, Columbus, OH. 11. St Jude's Children's Research Hospital, Memphis, TN. 12. Hospital for Sick Children, Toronto, ON, Canada. 13. Children's Hospital Colorado and the Department of Pediatrics, University of Colorado School of Medicine, Aurora, CO. 14. Division of Pediatric Hematology/Oncology, Children's Hospital of Eastern Ontario, Ottawa, ON. 15. Department of Pediatrics and Perlmutter Cancer Center, New York University Langone Medical Center, New York, NY. 16. University of Texas Southwestern Medical Center, Dallas, TX. 17. Department of Pediatrics, Benioff Children's Hospital, and the Helen Diller Family Comprehensive Cancer Institute, University of California, San Francisco, San Francisco, CA. 18. Department of Pediatrics and the Center for Childhood Cancer Research, The Children's Hospital of Philadelphia and the Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA.
Abstract
PURPOSE: AALL0932 evaluated two randomized maintenance interventions to optimize disease-free survival (DFS) while reducing the burden of therapy in children with newly diagnosed NCI standard-risk (SR) B-acute lymphoblastic leukemia (B-ALL). METHODS: AALL0932 enrolled 9,229 patients with B-ALL; 2,364 average-risk (AR) patients were randomly assigned (2 × 2 factorial design) at the start of maintenance therapy to vincristine/dexamethasone pulses every 4 (VCR/DEX4) or every 12 (VCR/DEX12) weeks, and a starting dose of weekly oral methotrexate of 20 mg/m2 (MTX20) or 40 mg/m2 (MTX40). RESULTS: Five-year event-free survival and overall survival (OS) from enrollment (with 95% CIs), for all eligible and evaluable SR B-ALL patients (n = 9,226), were 92.0% (91.1% and 92.8%) and 96.8% (96.2% and 97.3%), respectively. The 5-year DFS and OS from the start of maintenance for randomly assigned AR patients were 94.6% (93.3% and 95.9%) and 98.5% (97.7% and 99.2%), respectively. The 5-year DFS and OS for patients randomly assigned to receive VCR/DEX4 (n = 1,186) versus VCR/DEX12 (n = 1,178) were 94.1% (92.2% and 96.0%) and 98.3% (97.2% and 99.4%) v 95.1% (93.3% and 96.9%) and 98.6% (97.7% and 99.6%), respectively (P = .86 and .69). The 5-year DFS and OS for AR patients randomly assigned to receive MTX20 versus MTX40 were 95.1% (93.3% and 96.8%) and 98.8% (97.9% and 99.7%) v 94.2% (92.2% and 96.1%) and 98.1% (97.0% and 99.2%), respectively (P = .92 and .89). CONCLUSIONS: The 0NCI-SR AR B-ALL who received VCR/DEX12 had outstanding outcomes despite receiving one third of the vincristine/dexamethasone pulses previously used as standard of care on Children's Oncology Group (COG) trials. The higher starting dose of MTX of 40 mg/m2/week did not improve outcomes when compared with 20 mg/m2/week. The decreased frequency of vincristine/dexamethasone pulses has been incorporated into frontline COG B-ALL trials to decrease the burden of therapy for patients and their families.
PURPOSE: AALL0932 evaluated two randomized maintenance interventions to optimize disease-free survival (DFS) while reducing the burden of therapy in children with newly diagnosed NCI standard-risk (SR) B-acute lymphoblastic leukemia (B-ALL). METHODS: AALL0932 enrolled 9,229 patients with B-ALL; 2,364 average-risk (AR) patients were randomly assigned (2 × 2 factorial design) at the start of maintenance therapy to vincristine/dexamethasone pulses every 4 (VCR/DEX4) or every 12 (VCR/DEX12) weeks, and a starting dose of weekly oral methotrexate of 20 mg/m2 (MTX20) or 40 mg/m2 (MTX40). RESULTS: Five-year event-free survival and overall survival (OS) from enrollment (with 95% CIs), for all eligible and evaluable SR B-ALL patients (n = 9,226), were 92.0% (91.1% and 92.8%) and 96.8% (96.2% and 97.3%), respectively. The 5-year DFS and OS from the start of maintenance for randomly assigned AR patients were 94.6% (93.3% and 95.9%) and 98.5% (97.7% and 99.2%), respectively. The 5-year DFS and OS for patients randomly assigned to receive VCR/DEX4 (n = 1,186) versus VCR/DEX12 (n = 1,178) were 94.1% (92.2% and 96.0%) and 98.3% (97.2% and 99.4%) v 95.1% (93.3% and 96.9%) and 98.6% (97.7% and 99.6%), respectively (P = .86 and .69). The 5-year DFS and OS for AR patients randomly assigned to receive MTX20 versus MTX40 were 95.1% (93.3% and 96.8%) and 98.8% (97.9% and 99.7%) v 94.2% (92.2% and 96.1%) and 98.1% (97.0% and 99.2%), respectively (P = .92 and .89). CONCLUSIONS: The 0NCI-SR AR B-ALL who received VCR/DEX12 had outstanding outcomes despite receiving one third of the vincristine/dexamethasone pulses previously used as standard of care on Children's Oncology Group (COG) trials. The higher starting dose of MTX of 40 mg/m2/week did not improve outcomes when compared with 20 mg/m2/week. The decreased frequency of vincristine/dexamethasone pulses has been incorporated into frontline COG B-ALL trials to decrease the burden of therapy for patients and their families.
Authors: Bruce C Bostrom; Martha R Sensel; Harland N Sather; Paul S Gaynon; Mei K La; Katherine Johnston; Gary R Erdmann; Stuart Gold; Nyla A Heerema; Raymond J Hutchinson; Arthur J Provisor; Michael E Trigg Journal: Blood Date: 2003-01-16 Impact factor: 22.113
Authors: M Smith; D Arthur; B Camitta; A J Carroll; W Crist; P Gaynon; R Gelber; N Heerema; E L Korn; M Link; S Murphy; C H Pui; J Pullen; G Reamon; S E Sallan; H Sather; J Shuster; R Simon; M Trigg; D Tubergen; F Uckun; R Ungerleider Journal: J Clin Oncol Date: 1996-01 Impact factor: 44.544
Authors: K Schmiegelow; H Schrøder; G Gustafsson; J Kristinsson; A Glomstein; T Salmi; L Wranne Journal: J Clin Oncol Date: 1995-02 Impact factor: 44.544
Authors: Tamara P Miller; Kelly D Getz; Yimei Li; Biniyam G Demissei; Peter C Adamson; Todd A Alonzo; Evanette Burrows; Lusha Cao; Sharon M Castellino; Marla H Daves; Brian T Fisher; Robert Gerbing; Robert W Grundmeier; Edward M Krause; Judy Lee; Philip J Lupo; Karen R Rabin; Mark Ramos; Michael E Scheurer; Jennifer J Wilkes; Lena E Winestone; Douglas S Hawkins; M Monica Gramatges; Richard Aplenc Journal: Lancet Haematol Date: 2022-07-20 Impact factor: 30.153
Authors: Samuel W Brady; Kathryn G Roberts; Zhaohui Gu; Lei Shi; Stanley Pounds; Deqing Pei; Cheng Cheng; Yunfeng Dai; Meenakshi Devidas; Chunxu Qu; Ashley N Hill; Debbie Payne-Turner; Xiaotu Ma; Ilaria Iacobucci; Pradyuamna Baviskar; Lei Wei; Sasi Arunachalam; Kohei Hagiwara; Yanling Liu; Diane A Flasch; Yu Liu; Matthew Parker; Xiaolong Chen; Abdelrahman H Elsayed; Omkar Pathak; Yongjin Li; Yiping Fan; J Robert Michael; Michael Rusch; Mark R Wilkinson; Scott Foy; Dale J Hedges; Scott Newman; Xin Zhou; Jian Wang; Colleen Reilly; Edgar Sioson; Stephen V Rice; Victor Pastor Loyola; Gang Wu; Evadnie Rampersaud; Shalini C Reshmi; Julie Gastier-Foster; Jaime M Guidry Auvil; Patee Gesuwan; Malcolm A Smith; Naomi Winick; Andrew J Carroll; Nyla A Heerema; Richard C Harvey; Cheryl L Willman; Eric Larsen; Elizabeth A Raetz; Michael J Borowitz; Brent L Wood; William L Carroll; Patrick A Zweidler-McKay; Karen R Rabin; Leonard A Mattano; Kelly W Maloney; Stuart S Winter; Michael J Burke; Wanda Salzer; Kimberly P Dunsmore; Anne L Angiolillo; Kristine R Crews; James R Downing; Sima Jeha; Ching-Hon Pui; William E Evans; Jun J Yang; Mary V Relling; Daniela S Gerhard; Mignon L Loh; Stephen P Hunger; Jinghui Zhang; Charles G Mullighan Journal: Nat Genet Date: 2022-09-01 Impact factor: 41.307
Authors: Rozalyn L Rodwin; John A Kairalla; Emily Hibbitts; Meenakshi Devidas; Moira K Whitley; Caroline E Mohrmann; Reuven J Schore; Elizabeth Raetz; Naomi J Winick; Stephen P Hunger; Mignon L Loh; Marilyn J Hockenberry; Anne L Angiolillo; Kirsten K Ness; Nina S Kadan-Lottick Journal: J Natl Cancer Inst Date: 2022-08-08 Impact factor: 11.816
Authors: Tamara P Miller; Melissa Z Marx; Christopher Henchen; Nicholas P DeGroote; Sally Jones; Jenny Weiland; Beth Fisher; Adam J Esbenshade; Richard Aplenc; Christopher C Dvorak; Brian T Fisher Journal: J Patient Saf Date: 2022-04-01 Impact factor: 2.844
Authors: Laura J Janke; Jieun Kim; Monique A Payton; David A Jenkins; Xiangjun Cai; Emily R Finch; Yiwei Liu; Mary V Relling; Seth E Karol Journal: Pediatr Blood Cancer Date: 2021-06-14 Impact factor: 3.838
Authors: Jeremy M Schraw; J P Woodhouse; Melanie B Bernhardt; Olga A Taylor; Terzah M Horton; Michael E Scheurer; M Fatih Okcu; Karen R Rabin; Philip J Lupo; Austin L Brown Journal: Sci Rep Date: 2021-10-04 Impact factor: 4.379